Medical Pharmacology Practice Questions: Chapters 33-34 Targeted Therapeutics

The targeted chemotherapeutic approach(es) involve(s) which one(s) of the following?
1. Targeting malignant cells intracellular kinases
2. Targeting cancer cell growth factors and receptors
3. Targeting pathological tumor angiogenesis
4. Reversal abnormal immune system recognition of malignant cells.
5. A & B
6. A & C
7. B & C
8. A, B, C & D
Epidermal growth factor receptors (EGFR)
1. EGFR belongs to a family of transmembrane receptor tyrosine kinases.
2. Activation of EGFR results in increasing tyrosine kinase activity of the receptor with these phosphotyrosines stimulating several downstream signaling pathways.
3. Both
4. Neither
EGFR abnormalities due to mutations increased downstream signaling that results in both increased growth and survival advantages for cancer cells.
1. True
2. False
Example(s) of tyrosine kinase inhibitors that act to limit EGFR mutation mediated enhancement of downstream signaling in cancer cells includes/include:
1. Gefitinib (Iressa)
2. Erlotinib (Tarceva)
3. Both
4. Neither
Afatinib (Gilotrif) is an example of a tyrosine kinase inhibitor that limits EGFR mutation-mediated enhancement of downstream signaling in cancer cells.
1. True
2. False
Class/classes of drugs targeting the EGFR pathway and are thus valuable in solid tumor treatment:
1. Tyrosine kinase inhibitors
2. Agents that inhibit ligand-binding (extracellular) to EGFR.
3. Both
4. Neither
This drug is considered a "second-generation" tyrosine kinase inhibitor targeting EGFR kinase activity enhanced by malignant cell mutations.
1. Gefitinib (Iressa)
2. Erlotinib (Tarceva)
3. Afatinib (Gilotrif)
Cancer cells to become resistant to treatment with first or second generation EGFR kinase inhibitors are typically sensitive to osimertinib, a third-generation drug.
1. True
2. Paul's
Monoclonal antibodies may be lethal to tumor cells by means of which one/ones of the following:
1. Through promotion of immune cells and complement to the antigen-antibody complex
2. Through blocking cell surface receptor function
3. Through altering immune cell function.
4. All of the above
Protein kinase inhibitors used in treating cancer cells that exhibit abberant EGFR, exert their effect intracellularly.
1. True
2. Falls